Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
Alcohol dependent patients show comorbid psychiatric symptoms, related to malfunction of
dopamine, norepinephrine and serotonin neurotransmission, during early recovery. Ziprasidone
can improve malfunctioning of these disregulated systems, thereby improving anxiety,
depression, anhedonia, anger, and alcohol craving.
Phase:
Phase 3
Details
Lead Sponsor:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau